ea0089c26 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2022
Mallak Nadine
, Szidonya Laszlo
, Pegna Guillaume
, Pommier Rodney
, Mittra Erik
Background: Since their FDA-approval in 2018, both Lu177-DOTATATE and I131-MIBG radiopharmaceutical therapies are available at our institution for the treatment of pheochromocytoma and paraganglioma (PPGL). Tumor uptake of the radiopharmaceutical on pre-therapy imaging is a requirement for treatment. Here, we describe our experience with pre-therapy imaging, and how it relates to the tumor genotype and the therapeutic choice.Methods: This is a retrospect...